2579 results

• Colon Cancer Drugs Erbitux and Vectibix May Require Gene Screening

  December 16, 2008

  AboutLawsuits

  An FDA advisory panel is scheduled to meet today to review whether the drug labels for Erbitux and Vectibix, which...

• Vytorin Class Action Lawsuits Mount as Justice Deptartment Investigates

  November 5, 2008

  AboutLawsuits

  Merck & Co. and Schering-Plough Corp. currently face around 140 Vytorin class action lawsuits involving their once-popular cholesterol drug, which...

• Researcher Claims “No Credible Evidence” of Vytorin Cancer Side Effects

  September 19, 2008

  AboutLawsuits

  In response to concerns about a potential link between Vytorin and cancer, the FDA has initiated a safety review and...

• NEJM: Too Soon To Dismiss Vytorin Cancer Connection

  September 3, 2008

  AboutLawsuits

  According to an editorial published in the New England Journal of Medicine, it is too early to rule out concerns...

• FDA Investigating Link between Vytorin and Cancer

  August 22, 2008

  AboutLawsuits

  The FDA released an early communication yesterday, about an investigation into the possible association between cancer and Vytorin, Zetia and...

• Vytorin Cancer Risk Dismissed by Drug Makers

  July 24, 2008

  AboutLawsuits

  Merck & Co. and Schering Plough Corp., the joint marketers of the cholesterol drug Vytorin, have sent a letter to...

• FDA Highlights Regranex Foot Ulcer Gel Cancer Warnings

  June 9, 2008

  AboutLawsuits

  On Friday, the FDA announced a new “black box” warning for Johnson & Johnson’s Regranex foot gel. The prescription topical...

• Regranex Lawsuits

  June 9, 2008

  AboutLawsuits

  Regranex Gel has been linked to a substantially increased risk of death from cancer when three or more tubes are...

• FDA Investigates Possible Association of Enbrel, Humira and Remicade with Lymphoma Cancer in Children

  June 5, 2008

  AboutLawsuits

  The FDA is conducting a safety review of several medications used to treat arthritis, Crohn’s disease and other conditions among...